Charles Rivers Makes Organizational Changes - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Charles Rivers Makes Organizational Changes



Charles River Laboratories reports organizational changes, which are designed to improve the company’s productivity initiatives and promote the global management of its Research Models and Services (RMS) and Preclinical Services (PCS) businesses. The respective organizational changes are as follows:

Jörg Geller, DVM, PhD, previously corporate executive vice-president and president, European & Asian Operations, will now directly oversee a global initiative to improve efficiency and drive increased productivity across all of Charles River’s businesses. In his new role, Geller will assume the title of corporate executive vice-president global productivity and efficiency.

In conjunction with Geller assuming this new role, Davide Molho, DVM, previously corporate executive vice-president and president, North American Operations, will assume a broader range of responsibilities with global oversight of the RMS and PCS businesses. In his new role, Molho will assume the title of corporate executive vice-president and president, Global Research Models & Services and Preclinical Services Operations.

Colin Dunn, PhD, has been promoted to the position of corporate senior vice-president and general manager, RMS, Europe and Asia.  Dunn was previously responsible for European RMS operations, and in his expanded role, will oversee all of the company’s RMS operations in Europe, Japan, and China. Dunn will report to Molho, as will Brian Bathgate, corporate senior vice-president, European Preclinical Services. Bathgate will continue to oversee European preclinical operations as well as global PCS Laboratory Services.

Emily Hickey, who joined Charles River in October 2013 as corporate vice-president, In Vivo Discovery Research Services, will now report directly to Chairman, President, and CEO James Foster. This reporting change parallels the organizational structure that was previously established for the company’s endotoxin and microbial detection business. Foster Jordan, corporate senior vice-president, endotoxin and microbial detection, will continue to report directly to Foster.

Source: Charles River Laboratories

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes

Click here